Elite Pharma Reports 77% Revenue Growth, 151% Operating Income Surge for FY26
ELTP sits 21% above its 52-week low of $0.325.
Summary
Elite Pharmaceuticals announced robust financial results for fiscal year 2026, reporting $148.9 million in revenue, a 77% increase year-over-year. Operating income surged by 151% to $49.1 million. This strong performance was driven by the full-year contribution of Lisdexamfetamine and successful launches of Oxycodone Acetaminophen, Naltrexone, and Phentermine tablets. These significant financial improvements, following the 10-K filing earlier today, indicate strong operational execution and successful product commercialization. Management will host a conference call on June 30th at 11:30 AM EDT to discuss these results and provide further business updates.
At the time of this announcement, ELTP was trading at $0.40 on OTC in the Life Sciences sector, with a market capitalization of approximately $425.4M. The 52-week trading range was $0.33 to $0.78. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: TMX Newsfile.